MX383392B - Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). - Google Patents

Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).

Info

Publication number
MX383392B
MX383392B MX2019003520A MX2019003520A MX383392B MX 383392 B MX383392 B MX 383392B MX 2019003520 A MX2019003520 A MX 2019003520A MX 2019003520 A MX2019003520 A MX 2019003520A MX 383392 B MX383392 B MX 383392B
Authority
MX
Mexico
Prior art keywords
formulations
mixtures
alkyl ammonium
edta
ammonium salt
Prior art date
Application number
MX2019003520A
Other languages
English (en)
Other versions
MX2019003520A (es
Inventor
Catalin Nistor
Justas Barauskas
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1616366.9A external-priority patent/GB201616366D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2019003520A publication Critical patent/MX2019003520A/es
Publication of MX383392B publication Critical patent/MX383392B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mezclas que comprenden: i) al menos un lípido y/o al menos un aceite; y ii) una sal de EDTA de alquilamonio; en donde la mezcla tiene un contenido de agua en el intervalo de 0 a 1,0 % en peso. Mezclas que son preformulaciones, métodos de tratamiento que comprenden la administración de las preformulaciones, dispositivos de administración prellenados y kits que contienen las formulaciones, uso de una sal de EDTA de alquilamonio para reducir la descomposición de los componentes lipidicos y/o cualquier agente activo contenido dentro de la preformulación, y sales de EDTA de alquilamonio como se describe en la presente.
MX2019003520A 2016-09-27 2017-09-26 Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). MX383392B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16190892 2016-09-27
GBGB1616366.9A GB201616366D0 (en) 2016-09-27 2016-09-27 Formulations
PCT/EP2017/074418 WO2018060212A1 (en) 2016-09-27 2017-09-26 Mixtures and formulations comprising an alkyl ammonium edta salt

Publications (2)

Publication Number Publication Date
MX2019003520A MX2019003520A (es) 2019-11-11
MX383392B true MX383392B (es) 2025-03-13

Family

ID=59923462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003520A MX383392B (es) 2016-09-27 2017-09-26 Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).

Country Status (11)

Country Link
US (6) US11241476B2 (es)
EP (2) EP3518978A1 (es)
JP (1) JP7138626B2 (es)
KR (1) KR102611788B1 (es)
CN (2) CN109789215B (es)
AU (1) AU2017336199B2 (es)
CA (1) CA3038412A1 (es)
IL (2) IL265535B (es)
MX (1) MX383392B (es)
TW (2) TWI805558B (es)
WO (2) WO2018060213A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
PE20141484A1 (es) * 2011-05-25 2014-10-31 Camurus Ab Formulaciones peptidicas de liberacion controlada
AU2017336199B2 (en) 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
MX2021014450A (es) 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
WO2020240018A1 (en) 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN114831939B (zh) * 2021-01-30 2024-06-07 南京星银药业集团有限公司 一种醋酸曲安奈德组合物喷雾剂及其制备方法
IL308133A (en) * 2021-05-04 2023-12-01 Camurus Ab Compositions and methods for treating neuroendocrine tumors
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5313357B2 (es) 1974-05-07 1978-05-09
JPS51127693A (en) 1975-04-30 1976-11-06 Tech Res & Dev Inst Of Japan Def Agency Heat container mainly used for gas dinamic laser device
JPS5313357A (en) * 1976-07-22 1978-02-06 Toshiba Corp Formation of connector lead of semiconductor device
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
JP2000509404A (ja) 1996-05-08 2000-07-25 ニカ ヘルス プロダクツ リミテッド 遺伝物質の導入システムとしてのカチオン性ヴィロソーム
JP2002356464A (ja) * 2001-05-30 2002-12-13 Showa Denko Kk 高純度アミノポリカルボン酸及びその塩と製造方法
WO2005014777A2 (en) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
BRPI0409128A (pt) 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
AU2005324794C1 (en) 2003-11-07 2010-12-02 Camurus Ab Somatostatin analogue formulations
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
PL387296A1 (pl) 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
PE20141484A1 (es) * 2011-05-25 2014-10-31 Camurus Ab Formulaciones peptidicas de liberacion controlada
BR112014013693B1 (pt) 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
EP3045162B1 (en) 2012-07-26 2021-07-07 Camurus AB Opioid formulations
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
HK1245115A1 (zh) * 2014-12-10 2018-08-24 Amryt Endo, Inc. 口腔奥曲肽与其他治疗剂联合应用
CA2971642A1 (en) 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt

Also Published As

Publication number Publication date
JP7138626B2 (ja) 2022-09-16
IL295457A (en) 2022-10-01
TW201813662A (zh) 2018-04-16
US11135264B2 (en) 2021-10-05
KR102611788B1 (ko) 2023-12-12
US12257282B2 (en) 2025-03-25
KR20190084243A (ko) 2019-07-16
IL265535B (en) 2022-09-01
TWI805558B (zh) 2023-06-21
US20200138954A1 (en) 2020-05-07
CN109789214B (zh) 2022-06-28
TW201813631A (zh) 2018-04-16
AU2017336199B2 (en) 2020-08-20
CN109789214A (zh) 2019-05-21
US11241476B2 (en) 2022-02-08
RU2019110439A (ru) 2020-10-29
AU2017336199A1 (en) 2019-04-18
US11564968B2 (en) 2023-01-31
CN109789215A (zh) 2019-05-21
US20220168381A1 (en) 2022-06-02
CA3038412A1 (en) 2018-04-05
CN109789215B (zh) 2022-12-16
WO2018060213A1 (en) 2018-04-05
RU2019110439A3 (es) 2021-02-12
US20210008151A1 (en) 2021-01-14
US20190262419A1 (en) 2019-08-29
US20220257694A1 (en) 2022-08-18
US20250345385A1 (en) 2025-11-13
MX2019003520A (es) 2019-11-11
TWI756270B (zh) 2022-03-01
EP3518978A1 (en) 2019-08-07
WO2018060212A1 (en) 2018-04-05
JP2019529470A (ja) 2019-10-17
EP3518977A1 (en) 2019-08-07
IL265535A (en) 2019-05-30
AU2017336199A9 (en) 2019-05-23
US10688148B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
MX383392B (es) Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
MX2020011166A (es) Agentes crioprotectores para formulaciones en forma de particulas.
CO2018008829A2 (es) Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
PE20160004A1 (es) Metodo y aparato para tratamiento magnetico/electrostatico/electromagnetico de fluidos comprendiendo tres fases: la fase de tratamiento, la fase de mezcla y la fase de uso las cuales estan espacial y temporalmente desacopladas
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
BR112016022159B8 (pt) Pó e método para melhorar a aplicação tópica de um agente de benefício ácido
EA201400942A1 (ru) Топические композиции, содержащие фипронил и перметрин, и способы их применения
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
AR090646A1 (es) Uso de aminas para estabilizar trialquilalcanolaminas cuaternarias
MX2017003205A (es) Composiciones antimicrobianas y sus metodos de uso.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
EA202091502A1 (ru) СТИМУЛЯТОРЫ sGC
HRP20201354T1 (hr) Tekuće formulacije levotiroksina
MX2018012941A (es) Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano.
BR112018001486A2 (pt) ?composição de limpeza em barra, processo para preparar a composição, método para reduzir atividade antimicrobiana em uma superfície e uso da composição?
CO2020002624A2 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales
AR101581A1 (es) Composición de colutorio
UY37937A (es) Composiciones de dicamba con un potencial reducido de difusión de la pulverización
BR112018011157A2 (pt) composição agroquímica de suspensão aquosa.
UY40837A (es) Formulaciones de glifosato que contienen tensioactivos de amidoalquilamina
AR096082A1 (es) Complejación de iones de calcio en presencia de compuestos de amina cuaternizada mientras se acidifica una formación subterránea
DOP2019000276A (es) Compuesto de n-(4-piridil)nicotinamida o sal del mismo
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
MX2013015273A (es) Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol.